London, United Kingdom–(Newsfile Corp. – August 14, 2024) – Edison issues report on BB Biotech (SWX: BION).
BB Biotech, a Switzerland-based investment company, targets long-term capital growth from biotechnology companies developing and marketing innovative drugs. At least 90% of the portfolio is held in listed companies, primarily those that already have products on the market or promising drug candidates in advanced stages of development. BION is benchmarked against the Nasdaq Biotech Index (in CHF) but is managed on a bottom-up basis, with a focused c 20-35 stock portfolio.
Click here to read the full report.
All reports published by Edison are available to download free of charge from its website
www.edisongroup.com.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Joanne Collins +44 (0)20 3077 5700
Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219911
Dr. Amir Bajoghli and the Skin & Laser Dermatology Center are excited to announce the…
SAN FRANCISCO & BOSTON--(BUSINESS WIRE)--Audax Private Equity (“Audax”) announced today it has entered into a…
Revised system is designed to empower adjuster decision-making and increase productivity SAN DIEGO, Aug. 16,…
Global leader in high-validity real-world evidence for life sciences grows more than 3x in three…
Accelerates ongoing business transformation and sharpens Avantor's strategic focus Strengthens balance sheet with proceeds to…
CodaMetrix’s AI platform, developed with and used by 20 top U.S. health systems, efficiently and…